Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Early Health Technology Assessment (HTA) of Olpasiran and Pelacarsen for Secondary Prevention of Coronary Heart Disease (CHD)
Saved in:
| Published in: | ClinicoEconomics and Outcomes Research |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Early Health Technology Assessment (HTA) of Olpasiran and Pelacarsen for Secondary Prevention of Coronary Heart Disease (CHD)
- Unlocking the Potential of Health Technology Assessment (HTA) in Indonesian Midwifery: Challenges and Opportunities
- Atherogenic Index of Plasma’s Association with Coronary Heart Disease Risks Among Postmenopausal Pakistani Women
- Impact of the COVID‐19 Pandemic on Coronary Heart Disease Admissions and Mortality in Mexico: An Ecological Study
- Interpreting circulating microbiome-related metabolites in coronary heart disease
- National HTA system in Canada: From system analysis and understanding to system strengthening
- Effects of sugammadex on the coronary circulation: direct effects on coronary vessels or ...